Biosimilar Interchangeability May Be Losing Luster As Approval Goal

Pricing now may mean more to payers than whether the product is interchangeable.

Interchangeability may be losing its luster as a goal for biosimilar development.

Increasing concern and debate about drug costs seems to have made the FDA designation less desirable or less necessary to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics